MK 3328Alternative Names: [18F]MK-3328; MK-3328
Latest Information Update: 16 Jul 2016
At a glance
- Originator Merck & Co
- Class Antidementias; Fluorine compounds; Imaging agents; Oxazoles; Pyridines; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Belgium (IV, Injection)
- 06 Aug 2009 Phase-I clinical trials in Alzheimer's disease in Belgium (IV)